Eagle Strategies’s Bristol-Myers Squibb BMY Stock Holding History

Eagle Strategies’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-4,237	Closed	-$230K	–	222
2024 Q1	$230K	Buy	+4,237	New	+$216K	0.05%	242

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Eagle Strategies's BMY Position: Q2 2024 in Review

Eagle Strategies sold out of Bristol-Myers Squibb (BMY) in Q2 2024, closing a stake of 4,237 shares — an estimated $230K sold.

Eagle Strategies first reported a position in BMY in Q1 2024 and held it in 1 quarter. The position peaked at $230K in Q1 2024. 2,153 funds tracked by Wall St. Rank hold BMY as of Q2 2024.

Eagle Strategies reported no remaining Bristol-Myers Squibb position as of Q2 2024 after selling out during the quarter.
Eagle Strategies sold 4,237 Bristol-Myers Squibb shares in Q2 2024, an estimated $230K.
Eagle Strategies first reported a position in Bristol-Myers Squibb in Q1 2024 and held it in 1 quarter.
Eagle Strategies's Bristol-Myers Squibb position peaked at $230K in Q1 2024.
2,153 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2024.

Based on Eagle Strategies's 13F filing for Q2 2024, filed 8 Aug 2024.